Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG)

Autor:	Elena Pentsova, Linda M Bavisotto, Malbora Manne, Xuling Lin, Mariza Daras, Igor T. Gavrilovic, Antonio Omuro, Lisa M. DeAngelis, Jessica Hansen, Thomas Kaley, Ingo K. Mellinghoff, Andrew T. McKeown, Greg Gorman, Michael Lamson, Rashida A. Karmali
Rok vydání:	2016
Předmět:	Cancer Research Temozolomide business.industry Recurrent glioblastoma macromolecular substances Oncology Cancer research Medicine Carboxyamidotriazole Orotate Signal transduction business Nuclear medicine medicine.drug Calcium signaling
Zdroj:	Journal of Clinical Oncology. 34:2064-2064
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.2064
Popis:	2064Background: CTO is an oral inhibitor of non-voltage-dependent calcium signaling that results in simultaneous modulation of several receptor-mediated calcium-dependent signaling pathways. This s...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ba16e2223ae05a853f76a279e4307e3c https://doi.org/10.1200/jco.2016.34.15_suppl.2064 Zobrazit plný text záznamu